Alternatively, it has also been reported that tyrosine kinase inhibitors reduce the number of MDSCs in renal cell carcinoma (RCC) patients and hepatocellular carcinoma (HCC) by blocking VEGF, c-KIT, and STAT-3 (99–101). Here, VEGFA is linked to hepatocellular carcinoma.